- Current report filing (8-K)
12 Junho 2009 - 1:53PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
June 12,
2009
ALLOS
THERAPEUTICS, INC.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
|
|
|
|
|
11080
CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrants
telephone number, including area code:
(303)
426-6262
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8 Other Events
Item 8.01 Other
Events.
Allos Therapeutics, Inc., a Delaware corporation
(the Company), has distributed to its stockholders a proxy statement for its
2009 Annual Meeting of Stockholders to be held on June 23, 2009. Proposal 2 included in the proxy statement
relates to approval of an amendment to the Companys 2008 Equity Incentive Plan
(the Plan) to increase the aggregate number of shares of common stock
authorized for issuance under the Plan by 5,750,000 shares.
On June 12, 2009, the Compensation Committee of
the Board of Directors of the Company amended the Plan to provide that if the
exercise price of any stock award is satisfied by tendering shares of common
stock held by a participant (either by actual delivery or attestation), then
the number of shares so tendered shall not remain available for issuance under
the Plan. Prior to such amendment, the
Plan provided that if the exercise price of any stock award was satisfied by
tendering shares of common stock held by a participant (either by actual
delivery or attestation), then the number of shares so tendered would remain
available for issuance under the Plan.
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated: June 12, 2009
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
/s/ Marc H.
Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice
President, General Counsel
|
3
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024